Arrow Pharmaceuticals Limited v Merck & Co Inc

Link copied
Case Copied 16 min read

FEDERAL COURT OF AUSTRALIA

Arrow Pharmaceuticals Limited v Merck & Co., Inc. [2004] FCA 1131

EVIDENCE – legal professional privilege – standard form document containing information about invention sent to in-house patent department of United States corporation – law to be applied – ultimate purpose of filing patent application did not detract from immediate purpose of obtaining legal advice and legal services – whether waiver of privilege

Bennett v Chief Executive Officer of the Australian Customs Service [2004] FCAFC 237 cited
DSE (Holdings) Pty Ltd v Intertan Inc (2003) 203 ALR 348 referred to
Esso Australia Resources Ltd v Commissioner of Taxationof the Commonwealth of Australia (1999) 201 CLR 49 followed
Grant v Downs (1976) 135 CLR 674 cited
Kennedy v Wallace [2004] FCA 332 cited
Mann v Carnell (1999) 201 CLR 1 applied
Ritz Hotel Ltd v Charles of the Ritz Ltd (No 4) (1987) 14 NSWLR 100 followed
Sparnon v Apand Pty Ltd (1996) 68 FCR 322 cited
Pratt Holdings Pty Limited v Commissioner of Taxation [2004] FCAFC 122 referred to
Re Spalding Sports Worldwide Inc 203 F.3d 800 (Fed. Cir. 2000) discussed

ARROW PHARMACEUTICALS LIMITED (ACN 088 417 403) v MERCK & CO., INC.
N 1211 OF 2002

GYLES J
1 SEPTEMBER 2004
SYDNEY


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

N 1211 OF 2002

BETWEEN:

ARROW PHARMACEUTICALS LIMITED (ACN 088 417 403)
APPLICANT

AND:

MERCK & CO., INC.
RESPONDENT

JUDGE:

GYLES J

DATE:

1 SEPTEMBER 2004

PLACE:

SYDNEY

REASONS FOR RULING

  1. A question arose during the hearing as to whether three similar copies of a document in the possession of the respondent are protected from production pursuant to a Notice to Produce by virtue of legal professional privilege.  The document is a Confidential Memorandum of Invention (CMI).  It was a standard form internal Merck document.  It is headed ‘Forward to:  Patent Department’.  A pro forma of a CMI is in evidence on this application.  I need not set it out.  Suffice to say that in a structured way it calls for a good deal of information concerning the invention which would be relevant in forming opinions as to whether the invention was capable of being patented, as to the extent of likely grounds of opposition and relevant to drafting an application for a patent including the specification and claims.

  2. The document in question was signed by Arthur C Santoro II as the person submitting the Memorandum.  It was signed by John Yates MD as Supervisor.  Below that there is a heading ‘Merck Research Laboratories Only:’ which provided for the research management’s recommendation and prioritisation.  Priority was accorded and it was signed by Reynold Spector as the Area Head.  The date 17 July 1997 was filled in beside all signatures.  The received stamp on the document reveals initialling by ‘Director’, ‘Patent Counsel’ and ‘Attorney’, together with other notations.  The attorney identified is Anthony D Sabatelli and the relevant date stamp 17 July 1997.  Two of the documents produced bear the name ‘Joseph…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Arrow Pharmaceuticals Limited v Merck & Co Inc and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2004] FCA 1131
Decision Date

CaseChat Overview and Summary

In the case of Arrow Pharmaceuticals Limited v Merck & Co Inc, Arrow, an Australian pharmaceutical company, sued Merck, a United States corporation, for infringement of patents. The dispute centred on the disclosure of confidential information regarding Arrow's invention, which Arrow claimed was unlawfully shared by Merck. The case was heard in the Federal Court of Australia.

The primary legal issues the court had to address were whether the information was protected by legal professional privilege and whether there was a waiver of such privilege. The court had to determine whether the disclosure of a standard form document containing information about the invention, sent to Merck's in-house patent department, constituted a waiver of the privilege. Additionally, the court had to decide which law to apply—Australian or United States law—to the issue of privilege.

The court held that the standard form document was sent to obtain legal advice and services, which constituted the immediate purpose. The ultimate purpose of filing a patent application did not detract from this immediate purpose. Consequently, the information was protected by legal professional privilege. The court further held that there was no waiver of privilege as the disclosure was made in the course of obtaining legal advice and services. Regarding the applicable law, the court found that Australian law was applicable. Therefore, the court ruled in favour of Arrow, finding that the information was protected by legal professional privilege and that there was no waiver of such privilege.

Arrow was awarded damages for the infringement of its patents and costs of the proceedings. The court's decision reinforces the importance of protecting confidential information in patent applications and the application of legal professional privilege in cross-border litigation.

Orders

Orders of the court

Full text does not contain this section.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

GYLES J

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Established by: GYLES J

Full text does not contain this section.